Icotinib Combined With Shengmai Capsule In The Treatment Of Advanced Non-small Cell Lung Cancer

Objective: The purpose of our study was to observe therapeutic effect,KPS score,immune function and adverse effects of the first generation of EGFR-TKI targeting drug icotinib combined Shengmai capsule in the treatment of advanced NSCLC,and to investigate the clinical application value of the treatment.Methods: The 60 patients with EGFR-muant advanced NSCLC admitted to the respiratory department of the Affiliated Hospital of Hangzhou Normal University from January 2018 to September 2019 were randomly divided into two groups: the observed group and the control group,30 cases in each group.Both groups were given 125 mg oral doses of icotinib three times a day.On the basis of this,patients in the observed group were given 0.9g oral doses of Shengmai capsule three times a day.Therapeutic effect,KPS score and immune function of the two groups were observed after three months,then each month till disase progression or dead.Adverse effects and PFS of the two groups were observed.Results: The baseline date did not significantly differ between the observed group and the control group(P>0.05).(1) PFS was 12 months(95%CI: 9.48~14.52 months)in the observed group and 10 months(95%CI: 8.55~11.45 months)in the control group,PFS did significantly differ between the two groups(P=0.029).The ORR of the observed group was 73.33%,the DCR of this group was 93.33%,were significantly higher than those of the control group(P=0.009,P=0.020),the ORR of the control group was 40.00%,and the DCR of this group was 70.00%.(2)After treatment,the KPS score of the observed group was 81.00±7.12,and the control group was 74.00±6.22,were significantly improved(P=0.000,P=0.037).The KPS score before and after treatment in the observed group(13.67±12.17)was superior to the control group(4.67±11.67)(P=0.005).(3)After treatment,CD3+,CD4+ and CD4+/CD8+ in the observed group were significantly improved(P=0.000,P=0.002,P=0.000);but those before and after treatment in the control group were no difference(P=0.503,P=0.919,P=0.667);the immune function before and after treatment in the observed group were significantly higher compared with those in the control group(P=0.000,P=0.006,P=0.000).(4) Diarrhea,rash and leukopenia in the observed group were significantly less than those in the control group(P=0.033,P=0.044,P=0.044),but the incidence of thrombocytopenia did not significantly differ between the observed group(1/30)and the control group(3/30)(P=0.301).Conclusion: Compared with the control group,the combined of icotinib with Shengmai capsule for patients with EGFR-muant advanced non-small cell lung cancer can significantly improve the objective response rate and the disease control rate,extend the PFS of patients.It has less adverse reactions.It can improve the quality of life,immune function of patients.